WO2013140120A1 - Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole - Google Patents

Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole Download PDF

Info

Publication number
WO2013140120A1
WO2013140120A1 PCT/GB2013/000127 GB2013000127W WO2013140120A1 WO 2013140120 A1 WO2013140120 A1 WO 2013140120A1 GB 2013000127 W GB2013000127 W GB 2013000127W WO 2013140120 A1 WO2013140120 A1 WO 2013140120A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyridin
trifluoroethoxy
benzimidazole
sulphinyl
Prior art date
Application number
PCT/GB2013/000127
Other languages
English (en)
Inventor
Pathi L Srinivas
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Geena Malhotra
Shrinivas Madhukar Purandare
Chandrasekaran Ramasubbu
Manish Gangrade
Shashi Rekha Kanathala
Jennet JAYACHANDRAN
Original Assignee
Cipla Limited
King, Lawrence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Limited, King, Lawrence filed Critical Cipla Limited
Publication of WO2013140120A1 publication Critical patent/WO2013140120A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des nouvelles formes cristallines de (R)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lH-benzimidazole (Formule 1), des procédés pour leur préparation, des compositions pharmaceutiques les comprenant et l'utilisation de telles formes cristallines pour le traitement de troubles gastro-intestinaux (GI).
PCT/GB2013/000127 2012-03-22 2013-03-22 Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole WO2013140120A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN780/MUM/2012 2012-03-22
IN780MU2012 2012-03-22
IN204MU2013 2013-01-22
IN204/MUM/2013 2013-01-22

Publications (1)

Publication Number Publication Date
WO2013140120A1 true WO2013140120A1 (fr) 2013-09-26

Family

ID=48325758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/000127 WO2013140120A1 (fr) 2012-03-22 2013-03-22 Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole

Country Status (1)

Country Link
WO (1) WO2013140120A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US11077055B2 (en) 2015-04-29 2021-08-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219471A2 (fr) * 1985-07-03 1987-04-22 Halvor Forberg Arrangement dans un mélangeur
US5948789A (en) 1994-07-15 1999-09-07 Astra Aktiebolag Process for synthesis of substituted sulphoxides
US6462058B1 (en) 1999-06-17 2002-10-08 Takeda Chemical Industries, Ltd. Benzimidazole compound crystal
WO2006064283A1 (fr) * 2004-12-17 2006-06-22 Cipla Limited Composes et compositions pharmaceutiques
US20070004779A1 (en) 2000-05-15 2007-01-04 Hideo Hashimoto Process for producing crystal
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
US7285668B2 (en) 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
WO2009087672A1 (fr) 2007-12-18 2009-07-16 Watson Pharma Private Limited Procédé de préparation de r-lansoprazole amorphe stable
WO2009088857A1 (fr) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Formes solvatées de cristaux de (r) -2- [ [ [3-méthyl-4- (2, 2, 2-trifluoroéthoxy) -2-pyridinyl] méthyl] sulfinyl] -1h-benzimidazole
WO2009117489A1 (fr) 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Procédé de préparation du dexlansoprazole et autres formes polymorphes
WO2010039885A2 (fr) 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Formes cristallines du dexlansoprazole
WO2010056059A2 (fr) 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Nouveau dexlansoprazole cristallin et composition pharmaceutique comprenant ledit
WO2010079504A2 (fr) 2008-05-14 2010-07-15 Watson Pharma Private Limited Sel stable de r(+)-lansoprazole amine et son procédé de préparation
US20110009637A1 (en) 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011020189A1 (fr) 2009-08-19 2011-02-24 Apotex Pharmachem Inc. Formes de dexlansoprazole et procédés de préparation associés
WO2011092665A1 (fr) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Procédé pour la préparation de formes cristallines de dexlansoprazole
WO2011098938A1 (fr) 2010-02-11 2011-08-18 Orchid Chemicals And Pharmaceuticals Limited Nouveau solvate du dexlansoprazole
WO2011121546A1 (fr) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Sels de dexlansoprazole et leur élaboration
WO2011139414A2 (fr) 2010-04-27 2011-11-10 Dr. Reddy's Laboratories Ltd. Formes polymorphes de dexlansoprazole
US8318943B1 (en) * 2010-04-16 2012-11-27 Takeda Pharmaceuticals U.S.A., Inc. Sorbitol/dexlansoprazole co-crystals and method for making same

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219471A2 (fr) * 1985-07-03 1987-04-22 Halvor Forberg Arrangement dans un mélangeur
US5948789A (en) 1994-07-15 1999-09-07 Astra Aktiebolag Process for synthesis of substituted sulphoxides
EP0773940B1 (fr) 1994-07-15 2003-06-04 AstraZeneca AB Procede de synthese de sulfoxydes substitues
US6462058B1 (en) 1999-06-17 2002-10-08 Takeda Chemical Industries, Ltd. Benzimidazole compound crystal
US6664276B2 (en) 1999-06-17 2003-12-16 Takeda Chemical Industries, Ltd. Benzimidazole compound crystal
US20070004779A1 (en) 2000-05-15 2007-01-04 Hideo Hashimoto Process for producing crystal
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
US7285668B2 (en) 2000-12-01 2007-10-23 Takeda Pharmaceutical Company Limited Process for the crystallization of (R)- or (S)-lansoprazole
WO2006064283A1 (fr) * 2004-12-17 2006-06-22 Cipla Limited Composes et compositions pharmaceutiques
WO2009087672A1 (fr) 2007-12-18 2009-07-16 Watson Pharma Private Limited Procédé de préparation de r-lansoprazole amorphe stable
WO2009088857A1 (fr) 2007-12-31 2009-07-16 Takeda Pharmaceutical Company Limited Formes solvatées de cristaux de (r) -2- [ [ [3-méthyl-4- (2, 2, 2-trifluoroéthoxy) -2-pyridinyl] méthyl] sulfinyl] -1h-benzimidazole
US20100286400A1 (en) 2007-12-31 2010-11-11 Takeda Pharmaceutical Company Limited Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
WO2009117489A1 (fr) 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Procédé de préparation du dexlansoprazole et autres formes polymorphes
WO2010079504A2 (fr) 2008-05-14 2010-07-15 Watson Pharma Private Limited Sel stable de r(+)-lansoprazole amine et son procédé de préparation
WO2010039885A2 (fr) 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Formes cristallines du dexlansoprazole
US20100113527A1 (en) 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (fr) 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Nouveau dexlansoprazole cristallin et composition pharmaceutique comprenant ledit
US20110009637A1 (en) 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011020189A1 (fr) 2009-08-19 2011-02-24 Apotex Pharmachem Inc. Formes de dexlansoprazole et procédés de préparation associés
WO2011092665A1 (fr) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Procédé pour la préparation de formes cristallines de dexlansoprazole
WO2011098938A1 (fr) 2010-02-11 2011-08-18 Orchid Chemicals And Pharmaceuticals Limited Nouveau solvate du dexlansoprazole
WO2011121546A1 (fr) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Sels de dexlansoprazole et leur élaboration
US8318943B1 (en) * 2010-04-16 2012-11-27 Takeda Pharmaceuticals U.S.A., Inc. Sorbitol/dexlansoprazole co-crystals and method for making same
WO2011139414A2 (fr) 2010-04-27 2011-11-10 Dr. Reddy's Laboratories Ltd. Formes polymorphes de dexlansoprazole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUABING CHEN ET AL.: "Nanonization strategies for poorly water-soluble drug", DRUG DISCOVERY TODAY, vol. 00, no. 00, March 2010 (2010-03-01)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104650035A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 右兰索拉唑倍半水合物化合物
US11077055B2 (en) 2015-04-29 2021-08-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10835488B2 (en) 2016-06-16 2020-11-17 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Similar Documents

Publication Publication Date Title
JP2023012459A (ja) 共沈によるサブミクロン範囲内の非晶質固体分散物の製造方法
CN101137371B (zh) 制备兰索拉唑的方法
RU2595841C2 (ru) Композиции наноструктурированного апрепитанта, способ их получения и содержащие их фармацевтические композиции
US20050214371A1 (en) Stable pharmaceutical composition comprising an acid labile drug
KR20010022439A (ko) 항궤양 활성 화합물을 포함하는 경구용 약제학적 제제 및이의 제조방법
KR20040099298A (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
WO2012042224A2 (fr) Composition pharmaceutique
KR20020011997A (ko) 산에 불안정한 활성 화합물을 포함하는 신규 제제 및 투여형태
CA2796494A1 (fr) Compositions pharmaceutiques
US20130315988A1 (en) Pharmaceutical Composition
JP2010501642A (ja) カルシウム受容体−活性化合物の固体複合材料
US20090324728A1 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2017153958A1 (fr) Nouvelles formes polymorphes et forme amorphe d'olaparib
KR20140107302A (ko) 즉시 방출형 다중 유닛 펠릿 시스템
CN104224754A (zh) 一种达比加群酯药物组合物及其制备方法
JP2017511363A (ja) オレキシン受容体拮抗薬を含む固体分散体
WO2013140120A1 (fr) Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole
WO2012002547A1 (fr) Dispersion solide de bosentan
WO2010006904A2 (fr) Nouvelles formes cristallines du rabéprazole sodique
JP2023539729A (ja) Ｍａｌｔ１阻害剤の非晶質形態及びその製剤
CN108057036A (zh) 一种egfr抑制剂的固体药物组合物
WO2021018414A1 (fr) Composition pharmaceutique comprenant du dabigatran étexilate
EP1963306A2 (fr) Esomeprazole arginine
Tripathy et al. Solid dispersion: A technology for improving aqueous solubility of drug
KR100981751B1 (ko) 프란루카스트를 함유하는 과립 및 그의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13720997

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13720997

Country of ref document: EP

Kind code of ref document: A1